Savolitinib vs. Sunitinib in MET-driven PRCC.
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 180
Summary
- Conditions
- Carcinoma
- Carcinoma Renal Cell
- Enzyme Inhibitors
- Kidney Diseases
- Kidney Neoplasms
- Neoplasms by Site
- Protein Kinase Inhibitors
- Urologic Neoplasms
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03091192
- Collaborators
- Hutchinson MediPharma (HMP)
- Investigators
- Principal Investigator: Toni K Choueiri, MD Dana-Farber Cancer Institute
Get Well Soon